COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,362 Articles (22,803 medRxiv, 8,559 bioRxiv)

Most recent first Previous |  Page 1174: Articles 11731-11740  | Next

Leveraging machine learning and self-administered tests to predict COVID-19:An olfactory and gustatory dysfunction assessment through crowd-sourced data in India
Kumar, R., Singh, M., Singh, P., Parma, V., Ohla, K., Olsson, S. B., Saini, V., Rani, J., Kishore, K., Kumari, P., Ichhpujani, P., Sharma, A., Kumar, S., Sharma, M., Bhondekar, A. P., Kothari, A., Sardana, V., Iyengar, S., Dash, D., Kaur, R.
10.1101/2021.10.20.21265247 — Posted: 2021-10-26
ABO blood group type does not influence the level of SARS-CoV-2 antibody response in convalescent plasma donors
Ziberna, K., Jazbec, K., Jez, M., Mali, P., Rahne Potokar, U., Rozman, P.
10.1101/2021.10.19.21265195 — Posted: 2021-10-26
Response to the coronavirus disease 2019 (COVID-19) pandemic at private retail pharmacies in Kenya: a mixed methods study
Mugo, P. M., Mumbi, A. N., Munene, D., Nzinga, J., Molyneux, S., Barasa, E., Pharmaceutical Society of Kenya (PSK) COVID-19 Response Taskforce (CRT)
10.1101/2021.10.22.21265188 — Posted: 2021-10-26
Nanobodies recognizing conserved hidden clefts of all SARS-CoV-2 spike variants
Maeda, R., Fujita, J., Konishi, Y., Kazuma, Y., Yamazaki, H., Anzai, I., Yamaguchi, K., Kasai, K., Nagata, K., Yamaoka, Y., Miyakawa, K., Ryo, A., Shirakawa, K., Makino, F., Matsuura, Y., Inoue, T., Imura, A., Namba, K., Takaori-Kondo, A.
10.1101/2021.10.25.465714 — Posted: 2021-10-26
Structure, receptor recognition and antigenicity of the human coronavirus CCoV-HuPn-2018 spike glycoprotein
Tortorici, M. A., Walls, A. C., Joshi, A., Park, Y.-J., Eguia, R. T., Stevens-Ayers, T., Boeckh, M. J., Talenti, A., Lanzavecchia, A., Corti, D., Bloom, J. D., Veesler, D.
10.1101/2021.10.25.465646 — Posted: 2021-10-26
Targeting the chemokine receptor CXCR4 with histamine analogue to reduce inflammation in juvenile arthritis: a proof of concept for COVID-19 therapeutic approach
Bekaddour, N., Smith, N., Beitz, B., Llibre, A., Dott, T., Baudry, A., Korganow, A.-S., Nisole, S., Mouy, R., Breton, S., Bader-Meunier, B., Duffy, D., Terrier, B., Schneider, B., Quartier, P., Rodero, M., Herbeuval, J.-P.
10.1101/2021.10.24.465080 — Posted: 2021-10-26
COVID 19 breakthrough infection risk: a simple physical model describing the dependence on antibody concentration
Williams, D.
10.1101/2021.10.25.465798 — Posted: 2021-10-26
Neutralizing Antibody Response to Pseudotype SARS-CoV-2 Differs between mRNA-1273 and BNT162b2 COVID-19 Vaccines and by History of SARS-CoV-2 Infection
Tyner, H. L., Thompson, M. G., Burgess, J. L., Grant, L., Gaglani, M., Kuntz, J. L., Naleway, A. L., Thornburg, N. J., Caban-Martinez, A. J., Yoon, S. K., Herring, M. K., Beitel, S. C., Blanton, L., Nikolich-Zugich, J., Thiese, M. S., Flores Pleasants, J., Fowlkes, A. L., Lutrick, K., Dunnigan, K., Yoo, Y. M., Rose, S., Groom, H., Meece, J., Wesley, M. G., Schaefer-Solle, N., Louzado-Feliciano, P., Edwards, L. J., Olsho, L. E. W.
10.1101/2021.10.20.21265171 — Posted: 2021-10-26
COVID-19 Observations from Hospitalized Ward Patients in the Northern Emirates: A Practice Only Preached.
Qureshi, S., Kampani, D. D., Al-Qutbi, T. A. H.
10.1101/2021.10.20.21265254 — Posted: 2021-10-26
Mathematical modeling of COVID-19 in British Columbia:an age-structured model with time-dependent contact rates
Iyaniwura, S. A., Falcão, R. C., Ringa, N., Adu, P., Spencer, M., Taylor, M., Colijn, C., Coombs, D., Janjua, N. Z., Irvine, M., Otterstatter, M.
10.1101/2021.10.19.21265177 — Posted: 2021-10-26

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).